Key Takeaways

  • In a randomized dose-escalation clinical trial, inhaled LTI-03 was evaluated in people with idiopathic pulmonary fibrosis, marking a rare attempt to deliver a peptide therapy directly to the lung.
  • A phase 2 randomized controlled trial found that once-daily oral zenagamtide, a unimolecular GLP-1 and amylin receptor co-agonist, produced dose-dependent reductions in HbA1c in adults with type 2 diabetes.
  • A 12-month real-world French registry study reported that eptinezumab reduced migraine frequency in patients who had failed prior preventive treatments and were naïve to CGRP monoclonal antibodies.
  • A systematic review and meta-analysis concluded that tesamorelin reduced visceral adipose tissue in people living with HIV and lipodystrophy across multiple clinical trials.
  • A critical appraisal of clinical and preclinical evidence suggested GLP-1 receptor agonists may have neuroprotective properties relevant to diabetic neuropathy, though the authors noted the evidence base remains early-stage.

What is LTI-03 and why is inhaled delivery a big deal for lung fibrosis research?

LTI-03 is a first-in-class inhaled peptide therapeutic targeting IPF through local lung delivery of a lipidated, protease-resistant annexin A1 mimetic; the inhaled route matters because it concentrates drug directly at the fibrotic lesion while sidestepping the systemic exposure that has historically limited antifibrotic development. Inhaled LTI-03 trial

IPF is relentless. Median survival from diagnosis sits around three to five years, and the two approved oral agents — nintedanib and pirfenidone — slow progression without reversing it, carrying tolerability profiles that drive discontinuation in a meaningful fraction of patients. A peptide that reaches the alveolar epithelium directly, at pharmacologically relevant concentrations, without requiring systemic distribution to get there, represents a mechanistically distinct bet on the disease.

The delivery architecture is load-bearing, not cosmetic:

  • Target accessibility. The fibrotic niche in IPF is the distal lung — alveolar epithelial cells, myofibroblasts, and the extracellular matrix remodeling that connects them. Inhaled delivery deposits drug at that interface without relying on plasma concentration to drive tissue penetration. Inhaled LTI-03 trial
  • Systemic exposure reduction. Annexin A1 pathway modulation has pleiotropic anti-inflammatory effects; keeping drug local limits off-target engagement in tissues where those same pathways serve homeostatic functions.
  • Peptide stability engineering. LTI-03 incorporates lipidation and sequence modifications designed to resist the proteolytic environment of the inflamed, remodeling lung — a non-trivial challenge for any peptide delivered to an epithelial surface bathed in proteases. Inhaled LTI-03 trial

The annexin A1 axis itself is the mechanistic core. Annexin A1 is an endogenous glucocorticoid-regulated protein that resolves inflammation and, critically in the IPF context, modulates epithelial repair signaling. Dysregulated resolution — not merely excessive inflammation — is increasingly understood as central to fibrotic progression. LTI-03 is designed to pharmacologically restore that resolution signaling at the site where it has failed.

Inhaled peptide therapeutics face real formulation and stability hurdles that small molecules do not. The fact that LTI-03 advanced into a randomized dose-escalation study in IPF patients means those preclinical engineering problems were solved well enough to justify human exposure — a bar that filters out most candidates at the bench. Inhaled LTI-03 trial

This content is informational only and does not constitute medical advice, treatment recommendations, or clinical guidance of any kind.

What did the zenagamtide phase 2 trial find about this dual GLP-1/amylin peptide?

The phase 2 zenagamtide trial demonstrated statistically significant HbA1c reductions and dose-dependent weight loss in adults with type 2 diabetes, establishing proof-of-concept for oral unimolecular GLP-1/amylin receptor co-agonism. Here is what the data actually showed.

The trial was multicentre, randomised, double-blind, and placebo-controlled—a dose-finding study in adults with type 2 diabetes testing once-daily oral zenagamtide across multiple dose levels, designed explicitly to characterise the dose-response relationship before committing to a pivotal programme. The zenagamtide phase 2 trial reported that zenagamtide produced clinically meaningful HbA1c reductions relative to placebo, with effects scaling across the dose range examined.

Key findings from the zenagamtide phase 2 trial:

  • Glycaemic control: Zenagamtide reduced HbA1c in a dose-dependent manner versus placebo in adults with type 2 diabetes, confirming that dual GLP-1 and amylin receptor engagement translates to meaningful glycaemic activity in a human clinical setting.
  • Body weight: The trial observed dose-dependent body weight reductions. GLP-1 acts centrally and peripherally to slow gastric emptying and reduce appetite, while amylin signalling engages a distinct satiety pathway through area postrema circuits—complementary mechanisms that the weight loss data support.
  • Oral bioavailability: The compound was administered orally once daily. Achieving sufficient systemic exposure from an oral peptide to drive receptor-level pharmacology in both the GLP-1 and amylin axes is a non-trivial formulation achievement; the efficacy data confirm that exposure was pharmacologically relevant.
  • Safety and tolerability: The zenagamtide phase 2 trial characterised the safety profile across dose levels. Gastrointestinal adverse events—the class effect expected from GLP-1 receptor engagement—were observed, consistent with the mechanism.

The unimolecular architecture matters. Zenagamtide is a single peptide entity hitting both receptors, not a co-formulation, and that distinction carries real implications for pharmacokinetic predictability and regulatory path. The dose-finding design means the trial was not powered to be a definitive efficacy statement—it was built to identify doses worth advancing, and it did. The combination of HbA1c reduction and weight loss in a once-daily oral format, reported in the zenagamtide phase 2 trial, positions this molecule as a differentiated candidate in an increasingly crowded incretin space.

This content is for informational purposes only and does not constitute medical advice, treatment recommendations, or clinical guidance of any kind.

What does the eptinezumab registry data show for difficult-to-treat migraine?

Real-world registry data from the French FHU INOVPAIN cohort show that eptinezumab delivers clinically meaningful reductions in monthly migraine days and responder rates across a difficult-to-treat population — including patients who had already failed multiple prior preventive therapies — sustained over 12 months of prospective follow-up. This matters precisely because such populations are routinely excluded from or underrepresented in pivotal RCTs.

The FHU INOVPAIN registry enrolled migraine patients naïve to CGRP monoclonal antibodies but classified as difficult-to-treat, meaning prior preventive failures were the rule. Key findings across the 12-month observation window:

  • Monthly migraine day (MMD) reduction: The registry recorded significant decreases in MMDs from baseline, with reductions emerging early — consistent with eptinezumab's intravenous delivery mechanism, which achieves therapeutic plasma concentrations within hours of infusion rather than weeks.
  • ≥50% responder rates: A substantial proportion of patients met the ≥50% MMD reduction threshold, a benchmark the field treats as a marker of clinically meaningful response. The registry data tracked this across quarterly infusion cycles, allowing assessment of durability rather than acute response alone.
  • Prior treatment failure burden: Patients carried histories of multiple failed oral preventives. That eptinezumab produced responder-level outcomes in this group is the registry's central clinical argument — it positions the antibody as viable after conventional preventive exhaustion, not merely as a first-line alternative.
  • Safety profile: The 12-month prospective window captured no unexpected safety signals. The FHU INOVPAIN investigators reported the tolerability profile as consistent with what controlled trials had established.

The registry design carries standard observational limitations: no control arm, open-label ascertainment, and a French tertiary-center population that may not generalize broadly. Placebo response cannot be partitioned out. Twelve months of prospective real-world data in a treatment-refractory cohort is a different evidentiary animal than a 3-month RCT in a less-selected sample.

What the data don't resolve is whether the intravenous route itself — and the clinical encounter it necessitates — contributes to outcomes through adherence enforcement or contextual effects. That question remains open. The registry answers what happens. Mechanism attribution is a separate problem.

Disclaimer: This content is informational only and does not constitute medical advice, treatment guidance, or dosing recommendations. Consult a qualified healthcare professional for any medical decisions.

What do recent reviews say about tesamorelin, GLP-1 agonists, and metabolic peptide research?

Recent systematic reviews and early-phase trials converge on three signals: tesamorelin produces consistent, quantifiable metabolic benefit in HIV-associated lipodystrophy; semaglutide delivers clinically meaningful weight reduction in non-diabetic obesity; and the GLP-1 receptor agonist class is expanding its mechanistic footprint well beyond glycemic control.

Tesamorelin in HIV-associated lipodystrophy

A systematic review and meta-analysis pooling data from people living with HIV (PLWH) with lipodystrophy found that tesamorelin produced statistically significant reductions in visceral adipose tissue (VAT) compared with placebo. Researchers characterized the safety profile as acceptable, with no unexpected adverse signal patterns across the included trials. The review framed tesamorelin's benefit as specific to the HIV-lipodystrophy phenotype — a population where VAT accumulation carries distinct cardiometabolic risk — rather than generalizing findings to broader metabolic disease contexts.

Semaglutide in non-diabetic obesity

A meta-analysis of semaglutide in obese, non-diabetic patients confirmed efficacy for weight reduction, with pooled data supporting both the magnitude and durability of effect seen in individual trials. Reviewers explicitly addressed safety, finding the adverse event profile consistent with known GLP-1 receptor agonist class effects — predominantly gastrointestinal. For the peptide research community, this reinforces that GLP-1 receptor engagement drives weight loss independent of the glucose-lowering context in which these agents were originally developed.

GLP-1 receptor agonists: mechanistic expansion

The class is moving fast. A critical appraisal of GLP-1 receptor agonists and SGLT2 inhibitors (source) in diabetic neuropathy examined the therapeutic potential of both drug classes for a complication historically resistant to disease-modifying intervention. Researchers identified plausible mechanistic rationale — including neuroprotective and anti-inflammatory pathways — while appropriately flagging that clinical evidence in neuropathy remains early-stage and heterogeneous.

Unimolecular dual agonism: zenagamtide

The frontier is multi-receptor. A phase 2 randomized controlled trial of zenagamtide — an oral, once-daily unimolecular GLP-1 and amylin receptor co-agonist — in adults with type 2 diabetes demonstrated dose-dependent glycemic efficacy with a safety profile that supported continued development. Oral bioavailability of a peptide hitting two receptors simultaneously is not trivial. This trial represents a meaningful proof-of-concept that unimolecular dual agonism can survive the formulation challenge at clinical scale.

Taken together, these reviews map a field where established peptides like tesamorelin are being rigorously characterized in their target populations, while the GLP-1 scaffold continues to be engineered toward broader and more mechanistically ambitious applications.

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any medical decisions.

What is depemokimab and what does its pharmacokinetic modelling reveal?

Depemokimab is an ultra-long-acting anti-IL-5 monoclonal antibody engineered for once-every-six-month subcutaneous dosing. Population pharmacokinetic/pharmacodynamic (popPK/PD) modelling confirms that its extended half-life and target-mediated drug disposition (TMDD) kinetics support sustained IL-5 suppression across both severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in preclinical and early clinical models. The modelling work, published in a dedicated popPK/PD analysis, provides the quantitative backbone for understanding how a single 100 mg dose maintains biologically relevant exposure for 26 weeks.

Structural pharmacokinetics

The popPK/PD analysis characterised depemokimab disposition using a two-compartment model with TMDD, capturing the nonlinear elimination that dominates at low concentrations when IL-5 receptor-mediated clearance becomes saturable. Key structural features the model identified:

  • Half-life: Depemokimab's terminal half-life substantially exceeds that of mepolizumab (~16–22 days) and reslizumab (~24 days), enabling the 26-week interval.
  • TMDD contribution: At trough concentrations, target-mediated clearance contributes meaningfully to total elimination, meaning free IL-5 suppression is concentration-dependent in a way that flat-PK antibodies are not.
  • Subcutaneous bioavailability: The model estimated bioavailability consistent with typical IgG1 SC administration, with absorption kinetics that do not create a sharp Cmax spike—relevant for tolerability.

Covariates that matter

The popPK/PD analysis identified body weight and baseline blood eosinophil count as the primary sources of between-subject variability in both PK and PD response. Weight influenced central volume and clearance in the expected direction. Baseline eosinophil count shaped the PD trajectory: higher baseline counts required greater drug exposure to achieve equivalent suppression, because eosinophils themselves express IL-5 receptor α and contribute to TMDD sink capacity.

PD endpoint: blood eosinophil suppression

The pharmacodynamic model linked free IL-5 concentrations to blood eosinophil counts via an indirect-response framework. The popPK/PD analysis demonstrated that 100 mg SC every 26 weeks maintained near-complete eosinophil suppression throughout the dosing interval in the simulated patient population, with trough free-IL-5 concentrations remaining below the threshold associated with eosinophil recovery. That finding justifies the dosing interval clinically—not just the raw half-life number.

The model was built from data spanning both asthma and CRSwNP populations, and the popPK/PD analysis found no evidence of disease-specific differences in PK parameters, suggesting shared IL-5 biology drives exposure-response relationships across these type-2 inflammatory indications in the studied populations.

This section is for informational purposes only and does not constitute medical advice, dosing guidance, or treatment recommendations.

FAQ

What is LTI-03 and what disease is it being studied for?

LTI-03 is an inhaled peptide therapy that was evaluated in a randomized dose-escalation clinical trial in people with idiopathic pulmonary fibrosis (IPF), a progressive scarring lung disease. The study, published in Nature Communications, assessed safety and tolerability across dose levels; results are specific to that trial population and cannot be generalized as a treatment recommendation.

What makes zenagamtide different from existing GLP-1 drugs?

Zenagamtide is described in its Lancet phase 2 trial as a 'unimolecular' agonist—meaning a single molecule designed to activate both the GLP-1 receptor and the amylin receptor simultaneously. Most approved GLP-1 therapies target only the GLP-1 receptor. The trial found dose-dependent HbA1c reductions in adults with type 2 diabetes, but phase 2 data represent an early stage of evidence and larger trials are needed.

What is eptinezumab and how was it studied in the French registry?

Eptinezumab is an intravenously administered monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a signalling molecule involved in migraine. The FHU INOVPAIN registry followed migraine patients in France who were difficult to treat and had not previously used CGRP-targeting antibodies. Over 12 months, the real-world observational data showed reductions in monthly migraine days, though observational registry data carry different limitations than randomized controlled trials.

What did the tesamorelin meta-analysis find, and who was studied?

A systematic review and meta-analysis published in the Journal of the International Association of Providers of AIDS Care pooled data from clinical trials of tesamorelin—a synthetic analogue of growth hormone-releasing hormone—in people living with HIV who had lipodystrophy, a condition involving abnormal fat redistribution. The pooled analysis reported reductions in visceral adipose tissue. Meta-analyses reflect the quality and heterogeneity of their included trials and do not constitute clinical guidance.

What is depemokimab and what does its pharmacokinetic study tell researchers?

Depemokimab is a long-acting monoclonal antibody targeting interleukin-5 (IL-5), studied in people with asthma and chronic rhinosinusitis with nasal polyps. A population pharmacokinetics and pharmacodynamics analysis published in the Journal of Clinical Pharmacology modelled how the drug behaves across these patient populations, informing dosing interval decisions. Population PK/PD modelling is a computational tool that supports—but does not replace—direct clinical trial evidence.

Do GLP-1 receptor agonists help with diabetic neuropathy?

A critical appraisal published in Diabetology & Metabolic Syndrome reviewed preclinical and early clinical evidence suggesting GLP-1 receptor agonists may have neuroprotective effects relevant to diabetic neuropathy. The authors described the evidence as promising but noted it remains early-stage, with most mechanistic data coming from animal and in vitro models. No conclusions about clinical use can be drawn from an appraisal alone.

This article is for general information and is not medical advice. Many peptides discussed are research compounds not approved for human use — talk to a licensed clinician before using any peptide product.